DCM
OCUL icon

Defilade Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Defilade Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.6M Buy
1,490,286
+2,641
+0.2% +$23.9K 1.96% 22
2026
Q1 		$12.6M Buy
1,487,645
+805,982
+118% +$7.68M 1.77% 25
2025
Q4 		$8.28M Buy
+681,663
New +$8.28M 1.12% 29

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Defilade Capital Management's OCUL Position: Q2 2026 in Review

Defilade Capital Management increased its Ocular Therapeutix (OCUL) stake by 0.18% in Q2 2026, buying an estimated $23.9K and bringing the position to 1,490,286 shares worth $14.6M. The position accounts for 1.96% of the portfolio, ranked #22.

Defilade Capital Management first reported a position in OCUL in Q4 2025 and has held it in 3 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Defilade Capital Management held 1,490,286 shares of Ocular Therapeutix worth $14.6M as of Q2 2026.
  • Defilade Capital Management bought 2,641 Ocular Therapeutix shares in Q2 2026, an estimated $23.9K.
  • Ocular Therapeutix made up 1.96% of Defilade Capital Management's portfolio in Q2 2026, its #22 holding.
  • Defilade Capital Management first reported a position in Ocular Therapeutix in Q4 2025 and has held it in 3 quarters since.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.